Taxceph1 gm/10 ml

Taxceph 1 gm/10 ml is a third-generation cephalosporin antibiotic administered by injection (IM or IV) for the treatment of serious infections caused by susceptible bacteria. It is used only under the supervision of a healthcare professional in a hospital or clinical setting.

Established / FDA-approved uses

• Lower respiratory tract infections, including pneumonia
• Genitourinary tract infections
• Gynecologic infections
• Bacteremia/septicemia
• Skin and skin-structure infections
• Intra-abdominal infections (often used with an antibiotic active against anaerobes)
• Bone and joint infections
• Central nervous system infections, including bacterial meningitis
• Uncomplicated gonorrhea

Adjunct / combination uses

• Intra-abdominal infections and pelvic inflammatory disease, typically combined with an antibiotic covering anaerobic organisms (e.g., metronidazole)
• Perioperative prophylaxis to reduce the incidence of infection in patients undergoing contaminated or potentially contaminated surgical procedures

Use of Taxceph 1 gm/10 ml should be guided by culture and susceptibility testing whenever possible, and by local antibiotic resistance patterns.

Each vial of Taxceph 1 gm/10 ml for injection contains Taxceph 1 gm/10 ml sodium equivalent to Taxceph 1 gm/10 ml 250 mg, 500 mg, 1 g, or 2 g as a sterile powder for reconstitution, depending on the product strength.

Taxceph 1 gm/10 ml is a semi-synthetic, third-generation cephalosporin antibiotic for parenteral (injectable) use. It is bactericidal, acting by inhibiting bacterial cell wall synthesis, and has broad activity against many Gram-negative and Gram-positive organisms, including many beta-lactamase-producing strains.

Taxceph 1 gm/10 ml is supplied as a sterile powder that is reconstituted with an appropriate diluent and given by intramuscular (IM) or intravenous (IV) injection or infusion; it is not available as an oral formulation.

Taxceph 1 gm/10 ml belongs to the third-generation cephalosporin class of beta-lactam antibiotics.

Taxceph 1 gm/10 ml is a beta-lactam antibiotic that exerts a bactericidal effect by binding to penicillin-binding proteins (PBPs), thereby inhibiting the final transpeptidation step of bacterial cell wall (peptidoglycan) synthesis. This leads to cell lysis and death of susceptible bacteria.

Taxceph 1 gm/10 ml is stable against many beta-lactamases produced by Gram-negative bacteria, giving it a broader spectrum than earlier-generation cephalosporins, including activity against many Enterobacteriaceae, Haemophilus influenzae, Neisseria species, and many streptococci. It has good penetration into the cerebrospinal fluid when the meninges are inflamed, supporting its use in bacterial meningitis. Taxceph 1 gm/10 ml is partially metabolized to an active metabolite (desacetylTaxceph 1 gm/10 ml) and is eliminated primarily by the kidneys.

Taxceph 1 gm/10 ml is administered by a healthcare professional as a deep intramuscular injection or as a slow intravenous injection (over 3–5 minutes) or intermittent intravenous infusion (over 20–60 minutes). Rapid IV bolus injection in under 60 seconds via a central venous catheter should be avoided due to a risk of serious arrhythmia. It must not be mixed in the same syringe with aminoglycoside antibiotics.

• Aminoglycosides (e.g., gentamicin, tobramycin): Concurrent use with Taxceph 1 gm/10 ml may increase the risk of nephrotoxicity; renal function should be monitored, and the two drugs should not be mixed in the same syringe or infusion.
• Probenecid: Inhibits renal tubular secretion of Taxceph 1 gm/10 ml, increasing and prolonging its plasma concentrations.
• Nephrotoxic drugs (e.g., potent diuretics such as furosemide): Combined use with Taxceph 1 gm/10 ml may have an additive adverse effect on renal function.
• Live bacterial vaccines (e.g., typhoid, BCG): Antibiotics including Taxceph 1 gm/10 ml may reduce the efficacy of live bacterial vaccines; vaccination should generally be deferred until treatment is complete.

Common

• Injection site reactions: pain, inflammation, or induration after IM injection; phlebitis after IV administration
• Gastrointestinal upset: nausea, vomiting, diarrhea
• Rash, pruritus, or other mild hypersensitivity reactions
• Transient elevations in liver enzymes (AST, ALT)

Less common / serious

• Clostridioides difficile-associated diarrhea and colitis, which can range from mild to life-threatening and may occur during or up to several months after treatment
• Eosinophilia, transient neutropenia, or thrombocytopenia
• Serious hypersensitivity reactions, including anaphylaxis and Stevens-Johnson syndrome (rare)
• Interstitial nephritis
• Encephalopathy or seizures, particularly with high doses in patients with renal impairment

Taxceph 1 gm/10 ml crosses the placenta. Reproductive studies have not shown harm to the fetus, but adequate, well-controlled studies in pregnant women are limited; Taxceph 1 gm/10 ml should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus. Taxceph 1 gm/10 ml is excreted in low concentrations in breast milk; caution is advised, and a physician should be consulted before use during breastfeeding, considering possible effects on the infant's gut flora.

• Hypersensitivity/cross-reactivity: Before starting Taxceph 1 gm/10 ml, inquire carefully about prior hypersensitivity reactions to cephalosporins, penicillins, or other beta-lactams; cross-reactivity can occur, and caution is warranted in patients with a history of severe penicillin allergy (see Contraindications).
• C. difficile-associated diarrhea: Evaluate any diarrhea occurring during or after treatment, as it may represent pseudomembranous colitis (see Side Effects).
• Renal impairment: Dose reduction is required in significant renal impairment; monitor renal function during prolonged therapy.
• Prolonged use: Courses longer than about 10 days warrant periodic monitoring of blood counts for cytopenias.
• Injection technique: Avoid rapid IV bolus (under 60 seconds) via central venous catheters due to a risk of serious arrhythmia; do not co-administer with aminoglycosides in the same syringe or line.
• Stewardship: Take Taxceph 1 gm/10 ml exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

Overdose with Taxceph 1 gm/10 ml may cause exaggerated adverse effects, including neuromuscular hyperexcitability, seizures, or encephalopathy, particularly in patients with renal impairment. There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact emergency services/poison control; treatment is supportive, and hemodialysis may help remove the drug in severe cases.

Store unreconstituted Taxceph 1 gm/10 ml powder at room temperature (below 30°C), protected from light and moisture, and out of reach of children. Once reconstituted, use according to the healthcare facility's protocol; reconstituted solutions are generally stable for a limited time at room temperature and longer under refrigeration, per the manufacturer's instructions.

Renal impairment: Dose reduction is required in patients with significantly reduced creatinine clearance; see Dosage and Administration.

Hepatic impairment: No specific dose adjustment is generally required for hepatic impairment alone, but caution is advised in patients with combined hepatic and renal dysfunction.

Elderly: Dosing is generally the same as for other adults, adjusted for age-related decline in renal function.

Pregnancy and lactation: See Pregnancy and Lactation section.

Duration of Taxceph 1 gm/10 ml therapy is determined by the treating physician based on the type and severity of infection, typically ranging from 5–10 days, but may extend up to 14 days or longer for infections such as bacterial meningitis or endocarditis. The full prescribed course should be completed even if symptoms improve earlier.

Taxceph 1 gm/10 ml powder for injection must be reconstituted before use, following the healthcare facility's protocol and the manufacturer's instructions:

• For IM injection: Reconstitute with Sterile Water for Injection or 1% lidocaine solution (without epinephrine) as directed, to the appropriate concentration.
• For IV injection: Reconstitute with Sterile Water for Injection.
• For IV infusion: Further dilute in a compatible IV fluid such as 0.9% Sodium Chloride Injection or 5% Dextrose Injection.

Reconstituted solutions should be inspected visually for particulate matter and discoloration before administration and used within the stability window specified by the manufacturer.

Third-generation cephalosporin antibiotic (beta-lactam class).

Taxceph 1 gm/10 ml inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, disrupting the final cross-linking (transpeptidation) step of peptidoglycan formation, which results in bacterial cell lysis and death.

B

Taxceph 1 gm/10 ml is used in neonates, infants, and children for serious bacterial infections, including meningitis, using weight-based dosing (see Dosage and Administration). Dosing must be adjusted for age and body weight, and renal function should be considered in neonates. Safety and efficacy of Taxceph 1 gm/10 ml in premature infants have not been as extensively established as in term neonates and older children, and it should be used in this population under close medical supervision.